Filing summary: PharmAthene, Inc. 10-Q
Entity mismatch: The request identifies Altimmune, Inc., but the supplied filing is for PharmAthene, Inc. This summary reflects the filing text, not an Altimmune filing. The reporting period ended September 30, 2016; statements are unaudited.
Business context
PharmAthene describes itself as a biodefense company developing a next-generation anthrax vaccine. Its revenue primarily comes from U.S. government contracts, including an incrementally funded NIAID contract for SparVax-L. The company also reported substantial litigation proceeds from SIGA Technologies following a court judgment.
Financial results and liquidity
| Metric | Q3 2016 | Nine months 2016 | Comparable 2015 period |
|---|---|---|---|
| Contract revenue | $1.0 million | $4.1 million | $1.2 million and $9.4 million, respectively |
| Operating expenses | $5.0 million | $9.9 million | $2.8 million and $11.8 million, respectively |
| Operating loss | $4.0 million | $5.8 million | $1.7 million and $2.5 million, respectively |
| Other income, primarily SIGA litigation proceeds | $113.2 million | $121.9 million | $0.3 million for each period |
| Net income (loss) | $109.2 million | $116.1 million | $(1.3) million and $(2.2) million, respectively |
| Basic earnings (loss) per share | $1.68 | $1.79 | $(0.02) and $(0.03), respectively |
Net income chiefly reflects the one-time SIGA litigation recovery, rather than operating profitability. No gross margin is presented in the supplied statements.
- Cash and investments: At September 30, cash and cash equivalents were $69.1 million and short-term investments were $66.8 million, for $135.9 million combined. Cash was $15.6 million at December 31, 2015; there were no short-term investments reported then.
- Cash flow: Nine-month operating cash flow was $118.6 million, compared with cash used of $1.4 million in 2015. Investing activities used $66.9 million, primarily for short-term securities purchases; financing activities provided $1.8 million. Cash increased $53.5 million.
- Liquidity and debt: Current liabilities were $3.7 million, total liabilities $4.2 million, and stockholders’ equity $136.4 million. The filing reports no debt repayment in 2016 and no off-balance-sheet arrangements. Management said cash on hand, excluding SIGA proceeds intended for distribution, was expected to fund operations for at least 12 months.
Material changes versus prior periods
- Nine-month revenue fell to $4.1 million from $9.4 million. The filing attributes much of the prior-year comparison to BARDA audit-related revenue, including $5.8 million recorded in 2015; $0.8 million of additional audit revenue was recognized in Q2 2016.
- Research and development expense declined to $3.4 million for nine months from $4.0 million, partly reflecting the 2015 workforce and program realignment.
- General and administrative expense increased to $6.3 million from $5.2 million for nine months, with proposal/protest costs and higher stock-based compensation partly offset by lower SIGA legal costs. Q3 G&A rose to $3.7 million from $1.2 million.
- The company received $122.5 million from SIGA during the first nine months of 2016, recorded as litigation-related other income. The filing reports a further $10 million payment on October 6, 2016, after quarter-end.
Outlook, commentary, and risks
- The NIAID contract had approximately $11.2 million of approved funding after three options were exercised and runs through April 30, 2017. It could total approximately $28.1 million if all technical milestones are met and all eight options are exercised; future options are at NIAID’s discretion.
- After SIGA paid the additional $10 million in October, the filing states that $83.7 million remained due under an estimated total award of approximately $208.7 million. The amended deadline for SIGA to satisfy the judgment was November 30, 2016; unpaid balances accrued interest at 8.75%. The company cautioned that there was no assurance of further payment.
- If the full judgment is received in cash, the company said it expected, barring unexpected material events, to distribute at least 90% of after-tax net cash proceeds to stockholders. Timing and form were undecided. It intended afterward to seek a strategic transaction for its remaining assets and vaccine programs, with no assurance of a transaction or value increase.
- PharmAthene withdrew its protest of a DHHS vaccine solicitation after BARDA agreed to participate in discussions with NIAID and the company; those discussions were planned for the November 2016 annual review. The protest-related proposal, legal, and consulting costs were approximately $1 million.
- Key risks include collection and timing of the SIGA judgment, government funding or contract termination, achievement of NIAID milestones and options, product safety and efficacy, and preserving tax NOLs. The filing’s Risk Factors item states “None,” while its forward-looking discussion identifies these risks.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-Q is PharmAthene, Inc., not Altimmune, Inc.
- Check subsequent filings for SIGA payments, the remaining judgment balance, the November 30 deadline, and any changes to collection terms.
- Verify the amount and timing of any shareholder distribution, including tax treatment and board decisions; the stated 90% is conditional, not a declared distribution.
- Track NIAID funding, option exercises, technical milestones, and the outcome of the planned BARDA/NIAID discussions.
- Assess ongoing operating costs and cash runway apart from litigation proceeds, given low contract revenue and recurring operating losses.